EQT Life Sciences’ Post

C-sections are the most common major surgical procedure globally, with over 30 million performed each year. Innovation within this area of maternal health has the potential to improve the quality of care and reduce healthcare costs for millions. Against this backdrop, EQT Life Sciences has lead NUA SURGICAL's Series A funding round. Nua Surgical's surgical retractor, which is specifically designed for the unique dynamics of C-section surgery, aims to reduce the risk factors that lead to surgical complications, benefiting the patient, the clinician, and the healthcare system. Learn more about the investment here: https://lnkd.in/eWWsHfcz

First Human Case of Implantable Microsensor for Heart Failure The data generated by the implanted sensors will be aggregated and used by Heart Failure specialists to inform clinical decision making for these patients. "Heart Failure is characterized by periods of quiescence, followed by periods of deterioration, which require repeat hospitalizations. This ground-breaking technology will allow us to track patients' parameters in real time, to intervene earlier if needed and to reduce these patients' morbidity and mortality" said Dr. Tuvia Ben-Gal, Head of Heart Failure at Rabin Medical Center.

🌟 Exciting News from Microtech! 🌟 We are proud to announce a groundbreaking milestone in heart failure treatment. Microtech, a wholly owned subsidiary of Medinol, has successfully completed the First Human Case of Implantable Microsensor for Heart Failure.   The first implantation was performed by Prof. Erez Sharoni, Head of Cardio-Thoracic Surgery, at Beilinson Medical Center in Israel. This technology promises to revolutionize the standard of care for heart failure patients, offering earlier intervention and reducing hospitalizations. Stay tuned as we continue to innovate and improve healthcare for patients worldwide. 🌍💙 https://lnkd.in/dj_iU_vT #MedTech #Innovation #HeartFailure #Healthcare #Medinol

Newer developments in Med tech industry.

From an idea to a pioneering breakthrough in just 18 months! 🌟 Andromeda Surgical's journey from its inception to achieving the world's first robotic-assisted HoLEP in Chile is a testament to innovation and collaboration. This groundbreaking procedure, performed by Dr. Cristián Trucco at Universidad Católica de Chile, marks the beginning of the ASTRA clinical trial, setting a new standard in urological surgery. It's incredible to witness how Chile is emerging as a hub for medical device breakthroughs, offering unique opportunities for early feasibility trials. Did you know that bioaccess® is the only Medtech-only CRO facilitating these early trials in Chile and across Latin America? They're opening doors for Medtech startups to transform their visions into reality. As Andromeda continues to enhance their robotic platform, the future of surgical precision and accessibility looks promising. #MedTechInnovation #ClinicalTrials https://lnkd.in/gm4pAGh8

Minimally Invasive Surgery (MIS) makes this possible! By replacing traditional large incisions with advanced tools like laparoscopes and robotic systems, MIS transforms healthcare and puts patients on the fast track to recovery. 🌟 The Benefits of MIS: Quicker return to daily life Reduced risk of complications Enhanced surgical precision Better overall outcomes At AIMIS, we’re proud to lead the way, partnering with top surgeons and Centers of Excellence to drive advancements in women’s healthcare. 🚀 Take the next step toward surgical innovation: www.aimis.org #MinimallyInvasiveSurgery #SurgicalInnovation #AIMIS #TransformingHealthcare

𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 𝘁𝗵𝗮𝘁 𝗣𝗼𝘄𝗲𝗿 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 🤝⚡ Behind every groundbreaking idea are partnerships that make it a reality. Over our first 12 months, innovative collaborations with academic institutions and industry leaders have fueled progress, advancing surgical training and research – and helping OR-X thrive as a hub for innovation.    In the second part of our interview series, our co-founder Thomas Huggler explores the foundation of these partnerships and shares how they have shaped our journey so far. From the strength of shared goals to the milestones achieved together, he highlights 5 key takeaways that underscore the power of partnerships.    Take a closer look at his insights and discover how our collaborations are driving groundbreaking advancements in surgery and technology 👉 https://lnkd.in/eWWTKtuQ   #Partnerships #SurgicalInnovation #AdvancingSurgery #SurgicalExcellence #ORX

Transplant success isn’t just about the surgery; it’s about the journey afterward. What if you could track graft health with unmatched precision, ensuring peace of mind for both clinicians and patients? Why choose AlloSeq cfDNA? - Early Detection: Spot graft injuries before clinical symptoms appear.  - High Sensitivity: Monitor with confidence using precise donor-derived cfDNA measurement.  - Streamlined Workflow: Easy integration into routine lab practices.  - Proven Outcomes: Empowered by next-generation sequencing (NGS) technology. Science that Saves Lives: Stay ahead of graft dysfunction, improve outcomes, and elevate care standards—all with a single, simple blood draw. 

I'm delivering a free webinar on Thursday 5th December, 11:00 -12:00 to explore shared decision making (SDM) in perioperative care with the Personalised Care Institute: https://lnkd.in/gCXcHjM9 People considering surgery often face complex and difficult choices about their treatment options, which may range from doing nothing to undergoing high-risk surgery. That’s why SDM is essential in helping individuals make informed decisions about their surgical procedures. The webinar will cover enhanced understanding of SDM in the perioperative setting, putting SDM into context within NHS healthcare, key areas of research and service development, and resources for healthcare professionals to support SDM.

Now presenting at #InnovationSanDiego is Centese with CEO Evan Luxon. Centese (Omaha, NE, USA) is revolutionizing post-surgical care with Thoraguard®, the first autonomous system for managing thoracic drainage. Thoraguard provides automated fluid management and precise, real-time measurements, leading to shorter hospital stays with fewer complications. Proven in over 8,000 patients, Thoraguard sets a new standard for recovery following lung and heart surgery while streamlining clinical workflows and cutting costs for hospitals. Remain informed on new articles, conference updates and more with our helpful #medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI